Introduction {#s1}
============

Mitochondrial transport in axons is critical for the formation and function of the nervous system. This organelle generates the ATP necessary for energy demanding functions in all cells, but neurons are especially reliant on mitochondria to maintain their electrically polarized state. After depolarization, ATP-dependent ion pumps are employed to repolarize the cell and prepare it for another action potential. It is estimated that at rest alone, neurons use 4.7 billion molecules of ATP per second ([@bib59]). Because of this large ATP requirement, mitochondria need to be properly localized to regions of high ion influx, such as at synapses (reviewed in [@bib43]). In addition to their critical role in cellular metabolism, mitochondria also regulate local calcium ion levels ([@bib54]). Calcium efflux from intracellular stores mediates synaptic activity. During inactivity, this ion needs to be contained in intracellular compartments as high cytoplasmic calcium levels correlate with axonal degeneration ([@bib1]; [@bib50]; [@bib56]). The proper localization of mitochondria to sites of high ATP consumption and calcium ion flux requires active transport.

In addition to maintaining axon health, mitochondrial motility is also necessary to maintain mitochondrial health and function. Mitochondria undergo fission-fusion dynamics that facilitate both the replenishment of proteins in this organelle and the maintenance of mitochondrial DNA quantity and integrity (reviewed in [@bib39]). Interrupted mitochondrial fission or fusion has been linked to loss of mitochondrial DNA, loss of oxidative potential, and mitophagy. Axonal transport of mitochondria is tightly linked to mitochondrial dynamics as mitochondrial fusion requires the coalescence of mitochondria and fission requires the active separation of dividing organelles. The relationship between mitochondrial dynamics and transport is also apparent at the molecular level: Mitofusin, an essential protein for mitochondrial fusion, participates in the anterograde transport of this organelle as well ([@bib30]). Furthermore, manipulation of the dynamin-like protein Drp1, necessary for mitochondrial fission, impacts the localization of mitochondria ([@bib46]; [@bib49]). The mechanistic bases for these relationships are still largely unclear.

Elegant work in *Drosophila*, *C. elegans*, and cultured neurons has begun to elucidate the mechanisms of mitochondrial axonal transport. The primary anterograde mitochondrial motor, Kinesin-1, attaches to mitochondria via the proteins Miro (RhoT1/2; [@bib16]) and Milton (TRAK1/2; [@bib15]; [@bib47]). Miro contains calcium sensitive EF hands that, when exposed to high levels of this ion, change their confirmation, resulting in the uncoupling of the Kinesin-1 motor from microtubules ([@bib38]; [@bib52]). This mechanism, in conjunction with mitochondrial tethering factors ([@bib21]), allows mitochondrial congregation at sites of high synaptic activity. The Miro/Milton transport machinery is not specific for anterograde transport, however, as loss of either protein impacts anterograde and retrograde mitochondrial movement ([@bib16]; [@bib38]). Therefore, how mitochondria are specifically moved in a unidirectional manner by either the Kinesin or Dynein motor protein complex is not well understood.

Retrograde mitochondrial transport is known to depend on the cytoplasmic dynein complex ([@bib36]; [@bib40]). The core dynein motor (reviewed in [@bib17]) is oftentimes associated with dynactin, itself a multi-protein complex, during retrograde axonal transport. Dynactin, specifically its p150 subunit, has been shown to facilitate dynein processivity and also serves as an anchor for dynein at microtubule plus ends, facilitating cargo loading ([@bib24]; [@bib32]; [@bib42]). The dynactin accessory complex is attached to dynein through interaction of p150 with the tails of the dynein intermediate chains ([@bib51]). In addition to p150, dynactin contains two actin-related proteins, Arp1 and Actr10 (also known as Arp11; [@bib10]; [@bib11]). Together with p25, p62 and p27, Actr10 is a part of the dynactin pointed end complex which is predicted to be in an ideal location for cargo binding ([@bib57]). Structural work suggests that one key function for Actr10 is capping the actin-like Arp1 filament, to regulate filament length and facilitate attachment of other pointed end proteins ([@bib48]); however, this does not preclude an additional role for Actr10 in cargo attachment to the dynein complex, a function which has not been explored.

In a forward genetic screen for mediators of retrograde axonal transport, we identified a strain with a loss-of-function mutation in Actr10. *actr10^nl15^* mutants (hereafter referred to as *actr10*) display axon terminal swellings in the central and peripheral nervous systems indicative of retrograde transport abnormalities. Analysis of cargo localization and movement in the *actr10* mutant revealed clustering of mitochondria, but not other cargos analyzed, at microtubule plus ends due to failed retrograde mitochondrial movement. This phenotype was vastly different from loss of either Dynein heavy chain or p150, potentially indicating a unique function for Actr10 in mitochondrial retrograde movement. Furthermore, we demonstrated that abnormal mitochondrial movement in *actr10* mutants is due to failed attachment of mitochondria to the dynein-dynactin complex in the absence of Actr10. Importantly, Actr10 engineered to lack the dynactin binding domain maintains mitochondrial interaction, hinting at a specific role for Actr10 in mediating dynactin-mitochondria interaction. Finally, we provide biochemical and genetic evidence that Drp1, a Dynamin-related protein previously implicated in microtubule minus end-directed mitochondrial movement ([@bib45]), partners with Actr10 in mitochondrial retrograde transport. Together our data support a model in which Actr10 functions to scaffold mitochondria to the dynein-dynactin complex for retrograde transport in axons.

Results {#s2}
=======

Mitochondria accumulate in *actr10* mutant axon terminals due to failed retrograde transport {#s2-1}
--------------------------------------------------------------------------------------------

We used the zebrafish posterior lateral line (pLL) system to identify novel mediators of retrograde cargo transport in axons ([@bib9]). pLL axons develop early (axon extension is complete by 2 days post-fertilization (dpf) and synapse formation occurs by 4 dpf), are superficially localized and are largely planar, making them an ideal system for *in vivo* observations and manipulations ([Figure 1A](#fig1){ref-type="fig"}; [@bib14]; [@bib27]; [@bib28]). Using an ENU-based forward genetic screen, we isolated a larval-lethal, recessive mutant strain with large swellings in pLL axon terminals ([Figure 1B](#fig1){ref-type="fig"}). RNAmapper analysis ([@bib29]) identified the causal mutation as a single nucleotide change (T to G) in the start codon of *actr10*. We confirmed *actr10* as the affected gene using RNA-mediated rescue of axon terminal swellings and by performing TALEN- (Transcription Activator Like Effector Nuclease) mediated disruption of the first exon of *actr10*, which phenocopied the mutant axon terminal swellings ([Figure 1C--F](#fig1){ref-type="fig"}).10.7554/eLife.22234.002Figure 1.*actr10* mutants have swollen axon terminals.(**A**) Wild-type larva (pigment free) at 4 dpf carrying the *neurod:egfp* BAC transgene. By 4 dpf, pLL axons are fully extended and functional synapses have formed with hair cells of primary neuromasts. (**B**) *actr10* mutant axons fully extend but terminals display large swellings. Posterior lateral line ganglion (pLLg) and innervation of the third neuromast (NM3) are indicated. Insets in (**A**) and (**B**) show magnified NM3 axon terminals. Arrows in inset point to swellings. Asterisks label areas of the pLL nerve obscured by pigment in the mutant. (**C**) The mutant axon terminal swelling phenotype can be suppressed by exogenous expression of mRFP-Actr10 in a dose-dependent manner. Proportion of mutants with axon terminal swellings is depicted. (**D--F**) Injection of TALENS targeting exon 1 of the *actr10* genomic locus phenocopies the *actr10* mutant axon terminal swelling phenotype in F0 injected larvae (arrows). Axons are labeled by the *neurod:egfp* BAC transgene (white). Scale bars in A,B = 100 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.22234.002](10.7554/eLife.22234.002)

Axonal swellings, like those observed in *actr10* mutants, can arise due to a number of intracellular abnormalities, including disruptions in retrograde cargo transport ([@bib9]; [@bib26]). To determine if a particular cargo was accumulating in *actr10* mutant axon terminals, indicative of impaired retrograde movement, we performed immunolabeling on mutants and wildtype siblings at 4 dpf with antibodies against various axonal cargos. This revealed an accumulation of Cytochrome c, a mitochondrial protein, in *actr10* axon terminals ([Figure 2A,B,E](#fig2){ref-type="fig"}). To confirm mitochondrial accumulation in mutant axon terminals, mitochondria were labeled in neurons with TagRFP by zygotic injection of a plasmid containing a mitochondrial targeting sequence tagged with this fluorescent protein (*5kbneurod:mito-TagRFP*). *actr10* mutants displayed mitochondrial accumulation in pLL axon terminals ([Figure 2C,D](#fig2){ref-type="fig"}). Other known pLL axon retrograde cargos, including those labeled by Lamp1 (Lysosome associated membrane protein-1; late endosome/lysosome marker) and phosphorylated c-Jun N-Terminal Kinase (pJNK) did not accumulate ([Figure 2F--K](#fig2){ref-type="fig"}; [@bib9]). Expression of wildtype Actr10 using zygotic injection of *in vitro* synthesized mRNA rescued mitochondrial accumulation in *actr10* mutants ([Figure 2L--O](#fig2){ref-type="fig"}), confirming that Actr10 is necessary for proper mitochondrial positioning.10.7554/eLife.22234.003Figure 2.Loss of Actr10 causes mitochondrial accumulation in swollen axon terminals.(**A,B**) At 4 dpf, swollen axon terminals in *actr10* mutants (**B**) have high levels of Cytochrome c immunolabeling (arrow; NM3 shown) relative to a wildtype sibling (**A**). (**C,D**) TagRFP-labeled mitochondria accumulate in *actr10* mutant (arrow), but not wildtype, axon terminals at 4 dpf. (**E**) Mean fluorescence intensity (background subtracted) of Cytochrome C in axon terminals of A and B. (**F,G**) Mean fluorescence intensity (background subtracted) in axon terminals of H-K show comparable levels of Lamp1 and pJNK fluorescence intensity between wildtype and *actr10* mutant terminals (ANOVA; mean ± SEM shown). (**H--K**) Lamp1 and pJNK immunolabeling in NM3 axon terminals (arrows). Lamp1 and pJNK are in red in (**H--K**) and white in H\`-K\`. (**L--O**) Mitochondrial accumulation in mutant axon terminals, assayed using Cytochrome c immunolabeling (white), can be suppressed by mRNA-mediated expression of mRFP-Actr10. Arrows point to axon terminal regions for comparison. Scale bars = 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.22234.003](10.7554/eLife.22234.003)

As our immunolabeling experiments were not exhaustive for every possible cargo in axons, we undertook transmission electron microscopy (TEM) analyses of pLL axon terminals to determine if mitochondria are the predominant cargo mislocalized in *actr10* mutants. This experiment demonstrated mitochondria are highly enriched in the axon terminal swellings of *actr10* mutants compared to other intracellular structures ([Figure 3A,B](#fig3){ref-type="fig"}; n = 3 wildtypes, n = 4 mutants). Together, our immunolabeling and TEM analyses showing mitochondrial accumulation in axon terminals could indicate interrupted retrograde mitochondrial transport in *actr10* mutants.10.7554/eLife.22234.004Figure 3.TEM analysis of axon terminal swellings reveal mitochondrial accumulation.(**A**) Wild-type axon terminals innervating lateral line neuromasts showed no swellings (N = 3). (**B**) All neuromasts assayed in *actr10* mutants had mitochondrial laden axon terminal swellings (N = 4). A\` and B\` are higher magnification views of the areas outlined in A and B. Arrowheads in B\` point to mitochondria.**DOI:** [http://dx.doi.org/10.7554/eLife.22234.004](10.7554/eLife.22234.004)

To determine if mitochondrial retrograde transport was disrupted in *actr10* mutants, mitochondria in single pLL axons were tagged with TagRFP using *5kbneurod:mito-TagRFP* plasmid injection and organelle movement was visualized by confocal microscopy ([Figure 4A,B](#fig4){ref-type="fig"}; [Videos 1](#media1){ref-type="other"} and [2](#media2){ref-type="other"}). Kymograph analysis demonstrated a 37% and 39% reduction in the distance moved by mitochondria in the anterograde and retrograde directions respectively in *actr10* mutants but no change in mitochondrial transport velocity ([Figure 4C--F](#fig4){ref-type="fig"}). Despite the decrease in anterograde transport distance, the frequency of anterograde mitochondrial transport was unchanged in *actr10* mutants. We also analyzed reversal frequency to determine if there was a defect in directional persistence of mitochondrial transport in *actr10* mutants but found no difference in the proportion of mitochondria that reversed direction during our imaging sessions (wildtype: 0.011 ± 0.008; *actr10* mutants: 0.000 ± 0.009; ANOVA; *p*=0.4003). In contrast, both the frequency of retrograde mitochondrial transport and the proportion of mitochondria moving in the retrograde direction were dramatically decreased in *actr10* mutants ([Figure 4G,H](#fig4){ref-type="fig"}). As velocity of movement was largely normal, these data suggest a role for Actr10 in the attachment of mitochondria to the retrograde motor for transport.10.7554/eLife.22234.005Figure 4.Mitochondrial retrograde transport is specifically disrupted in *actr10* mutants.(**A,B**) Stills from [Videos 1](#media1){ref-type="other"} and [2](#media2){ref-type="other"} of mitochondrial transport in single pLL axons of a wildtype (**A**) and *actr10* mutant (**B**). Yellow and red arrowheads point to mitochondria moving in the anterograde and retrograde directions respectively. (**C,D**) Kymograph analyses of mitochondrial transport in wildtype (**C**) and *actr10* mutants (**D**). (**E,F**) Distance and velocity of mitochondrial transport in *actr10* mutants (Ant-anterograde; Ret-retrograde; ANOVA). (**G**) The number of mitochondria moving in the retrograde direction is significantly reduced in *actr10* mutants (ANOVA; *p*\<0001). (**H**) The proportion of mitochondria moving in the retrograde, but not anterograde, direction is reduced in *actr10* mutants (ANOVA with post-hoc contrasts; *p*\<0.01). Scale bars = 10 µm. Error bars represent mean ± SEM. Number of larvae assayed (biological replicates) is indicated on graphs.**DOI:** [http://dx.doi.org/10.7554/eLife.22234.005](10.7554/eLife.22234.005)Video 1.Mitochondrial transport in a 4 dpf wildtype larva, related to [Figure 4](#fig4){ref-type="fig"}.Yellow arrowheads indicate mitochondria moving in the anterograde direction. Red arrowhead marks retrograde mitochondrial movement. Scale bar = 10 µm**DOI:** [http://dx.doi.org/10.7554/eLife.22234.006](10.7554/eLife.22234.006)10.7554/eLife.22234.006Video 2.Mitochondrial transport in a 4 dpf *actr10* mutant larva, related to [Figure 4](#fig4){ref-type="fig"}.Yellow arrowheads indicate mitochondria moving in the anterograde direction. Scale bar = 10 µm**DOI:** [http://dx.doi.org/10.7554/eLife.22234.007](10.7554/eLife.22234.007)10.7554/eLife.22234.007

Actr10 functions autonomously in neurons to regulate axon morphology and mitochondrial localization {#s2-2}
---------------------------------------------------------------------------------------------------

*actr10* is ubiquitously expressed, albeit enriched in the nervous system during larval stages ([Figure 5A--C](#fig5){ref-type="fig"}). As neuronal activity and the presence of growth factors can modulate mitochondrial transport ([@bib2]; [@bib4]), it was possible that changes in the axonal environment in *actr10* mutants could alter mitochondrial movement. This led us to ask if Actr10 functions autonomously in axons to regulate mitochondrial transport. To test for a neuron-specific function for Actr10 in mitochondrial localization, we expressed monomeric red fluorescent protein (mRFP) tagged Actr10 in individual pLL neurons using zygotic injection of a *5kbneurod:mRFP-actr10* DNA plasmid and assessed axon terminals. While mRFP-Actr10 expression in wildtype axons had no apparent effects ([Figure 5D](#fig5){ref-type="fig"}; n = 6 in 3 biological replicates), it rescued axon terminal morphology and mitochondrial localization in all mutants analyzed ([Figure 5E--G](#fig5){ref-type="fig"}; n = 5 mutants in 3 biological replicates). These experiments confirmed a neuron-specific function for Actr10 in mitochondrial localization in axons.10.7554/eLife.22234.008Figure 5.Actr10 functions cell autonomously in axons.(**A--C**) Expression of *actr10* mRNA was assayed using *in situ* hybridization with DIG-labeled riboprobes and alkaline phosphatase-mediated NBT/BCIP precipitation. *actr10* is ubiquitously expressed at all time points tested, with elevated expression in the nervous system at later stages (3 and 5 dpf). Arrows point to the pLL ganglion in B and C. (**D**) Neuronal mRFP-Actr10 expression does not alter axon morphology or mitochondrial localization in wildtype larvae at 4 dpf. Mitochondria were visualized by Cytochrome c immunolabeling in NM3 axon terminals. (**E**) Uninjected *actr10* mutants have high levels of Cytochrome c immunolabling in NM3 axon terminals at 4 dpf. (**F**) mRFP-Actr10 expression in *actr10* mutant neurons suppressed axon terminal swellings and mitochondrial accumulation. Yellow arrowhead points to the region of the axon terminal expressing mRFP-Actr10. Note that mRFP-Actr10 negative axon terminals (red arrowhead) display axonal swelling and high levels of Cytochrome c labeling. Lines in D\`\`, E\`\` and F\`\` indicate regions used for line scan analysis. (**G**) Line scans show that mRFP-Actr10 expression rescues Cytochrome c levels in *actr10* mutant axons (compare pink/red and yellow lines). Pigment cells (\*) obscure some nerves. Scale bars = 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.22234.008](10.7554/eLife.22234.008)

Dynein localization and motility does not rely on Actr10 {#s2-3}
--------------------------------------------------------

Previous work on Actr10 function assayed mitotic spindle positioning during cell division in cultured fibroblasts and nuclear positioning in fungi to show that Actr10 depletion phenocopied dynein loss of function ([@bib23]; [@bib57]; [@bib58]). In association with structural work implicating Actr10 in Arp1 filament capping ([@bib48]), these data could imply that loss of Actr10 impacts dynactin integrity and, subsequently, all dynein function. However, the aforementioned work could also be interpreted to mean that appropriate dynactin-nuclear membrane interaction requires Actr10 function. Supporting this possibility, Actr10 has been shown to regulate dynactin-membrane association ([@bib5]). With this data in mind, we next wanted to determine if loss of Actr10 phenocopied dynein or dynactin loss of function in mature neurons, the cell type that displayed specific defects in mitochondrial retrograde transport in our studies. First, we analyzed the localization of dynein and dynactin in *actr10* mutant axons at 4 dpf. Neither Dynein heavy chain (DHC) nor p150 were significantly mislocalized in *actr10* mutants, though we did observe a trend of increased DHC in *actr10* mutant axon terminals ([Figure 6A--F](#fig6){ref-type="fig"}). Next, to determine if dynein was able to move in the retrograde direction, we assayed dynein motility by tagging the core motor complex using expression of an mRFP tagged variant of dynein light intermediate chain (*5kbneurod:dync1li1V2-mRFP*; [Figure 6G,H](#fig6){ref-type="fig"}; [Videos 3](#media3){ref-type="other"} and [4](#media4){ref-type="other"}). Kymograph analysis revealed no change in the parameters of retrograde dynein movement, though we did note a 42% reduction in the distance and a 26% reduction in the velocity of *anterograde* dynein transport. Despite these defects in anterograde dynein transport, there was no change in the proportion of dynein-positive puncta moving in the anterograde or retrograde direction in *actr10* mutants at 4 dpf ([Figure 6I--M](#fig6){ref-type="fig"}). Additionally, we analyzed reversal frequency to determine if there was a defect in persistence of dynein movement in *actr10* mutants but found no difference in the average number of puncta that reversed direction during our imaging sessions (wildtype: 1.62/100 µm\*min ±0.37; *actr10* mutants: 1.74/100 µm\*min ±0.44; ANOVA; *p*=0.844). These experiments demonstrated that loss of Actr10 does not impede dynein-dynactin complex localization or dynein retrograde movement in axons.10.7554/eLife.22234.009Figure 6.Dynein-dynactin localization and retrograde movement are intact in *actr10* mutants.(**A,B**) Dynein heavy chain (DHC) immunolabeling demonstrates normal DHC localization in NM3 axon terminals of *actr10* mutants at 4 dpf. (**C,D**) p150 is normally localized in NM3 axon terminals of *actr10* mutants at 4 dpf. (**E,F**) Analyses of mean fluorescence intensity in axon terminals (background subtracted) showed comparable fluorescence intensity between mutant and wildtype siblings (ANOVA; mean ± SEM shown). (**G,H**) Stills from dynein time-lapse imaging sessions ([Videos 3](#media3){ref-type="other"} and [4](#media4){ref-type="other"}) in wildtype and *actr10* mutant pLL axons at 4 dpf. Arrowheads indicate retrograde dynein movement. (**I,J**) Kymograph analyses of dynein transport in wildtype (**I**) and *actr10* mutants (**J**). (**K--M**) Retrograde dynein transport parameters, including the proportion of dynein-labeled vesicles (**K**), distance moved by vesicles (**L**) and velocity of movement (**M**) are unaffected in *actr10* mutants (ANOVA; mean ± SEM shown). A reduction of anterograde dynein-positive puncta distance and velocity was noted (ANOVA; mean ± SEM shown). (**N**) Dynein intermediated chain 2b fused to GFP (i2b-GFP) interacts with the core dynein complex. Immunoprecipitation of i2b-GFP from whole embryo extracts followed by DHC western (top). Whole embryo lysate controls for i2b-GFP (middle; top band not present in wildtype) and DHC (bottom). Bead only (no 1°) immunoprecipitation controls shown. (**O**) The core dynein complex labeled by i2b-GFP can immunoprecipitate p150 from whole larval lysates derived from wildtype and *actr10* mutant larvae at 4 dpf (top). Whole larval lysate control for i2b-GFP (middle) and p150 (bottom). Bead only (no 1°) and un-injected wildtype immunoprecipitation controls shown. Scale bars = 10 µm. Number of larvae assayed is indicated on graphs.**DOI:** [http://dx.doi.org/10.7554/eLife.22234.009](10.7554/eLife.22234.009)Video 3.Dynein motility in a 4 dpf wildtype larvae, related to [Figure 6](#fig6){ref-type="fig"}.Red arrowheads indicate dynein positive cargo moving in the retrograde direction. Scale bar = 10 µm**DOI:** [http://dx.doi.org/10.7554/eLife.22234.010](10.7554/eLife.22234.010)10.7554/eLife.22234.010Video 4.Dynein motility in a 4 dpf *actr10* mutant larva, related to [Figure 6](#fig6){ref-type="fig"}.Yellow arrowhead indicates dynein positive puncta being passively carried in the anterograde direction. Red arrowheads mark dynein positive cargo moving in the retrograde direction. Scale bar = 10 µm**DOI:** [http://dx.doi.org/10.7554/eLife.22234.011](10.7554/eLife.22234.011)10.7554/eLife.22234.011

We then analyzed the stability of dynein-dynactin interaction using co-immunoprecipitation from whole larval extracts. Immunoprecipitation of endogenous proteins was not possible due to lack of zebrafish-specific antibodies, so we turned to overexpression of tagged dynein components using zygotic injection of *in vitro* synthesized mRNA. First, we confirmed that a GFP tagged version of dynein intermediate chain 2b (i2b), a core dynein protein, could integrate into the motor complex. mRNA encoding i2b-GFP was injected into zygotes and anti-GFP antibodies were used to immunoprecipitate the complex. Extracts were subjected to western blot analysis and probed with anti-DHC antibodies. i2b-GFP can integrate into the core dynein complex ([Figure 6N](#fig6){ref-type="fig"}). We then used this approach to determine if loss of Actr10 impacts dynein-dynactin interaction. i2b-GFP was expressed in *actr10* mutants and wild-type siblings and larval extracts were subjected to GFP-based immunoprecipitation at 4 dpf. Western blot of larval extracts revealed no change in p150 interaction with the core dynein motor ([Figure 6O](#fig6){ref-type="fig"}). Together, these experiments confirmed that loss of Actr10 does not impact dynein-dynactin interaction.

To further explore the effect of loss of Actr10 on retrograde cargo transport, we analyzed the movement of additional dynein cargos in axons. First, we visualized peroxisome transport in lateral line axons ([Videos 5](#media5){ref-type="other"} and [6](#media6){ref-type="other"}). Kymograph analysis of peroxisome transport at 4 dpf demonstrated small changes in anterograde transport velocity and distance of retrograde transport bouts ([Figure 7A--G](#fig7){ref-type="fig"}). A slight, but not significant decrease in the proportion of peroxisomes moving in the retrograde was apparent as well ([Figure 7G](#fig7){ref-type="fig"}; ANOVA; *p*=0.07). Upon further investigation, we found that previous studies revealed a surprising relationship between mitochondria and peroxisomes, including a large number of shared membrane proteins, such as Drp1 (reviewed in [@bib41]). Our work implicates Drp1 in Actr10-dependent mitochondrial localization (see Figure 12), making the impact of Actr10 loss of function on peroxisome transport complex. Therefore, we analyzed the transport of a third cargo, Lamp1-labeled vesicles, which are composed of late endosomes and lysosomes. Analysis of Lamp1-positive vesicle movement at 4 dpf demonstrated that this cargo is transported normally in *actr10* mutant axons ([Figure 7H--L](#fig7){ref-type="fig"}). These live imaging experiments, in conjunction with the immunolabeling of known retrograde cargos ([Figure 2](#fig2){ref-type="fig"}) and our TEM studies ([Figure 3](#fig3){ref-type="fig"}), argue that loss of Actr10 does not hinder the transport of all dynein-dependent, retrograde cargos in axons.10.7554/eLife.22234.012Figure 7.Peroxisome and Lamp1 vesicle transport in *actr10* mutants at 4 dpf.(**A,B**) Stills from peroxisome imaging sessions at 4 dpf from [Videos 5](#media5){ref-type="other"} and [6](#media6){ref-type="other"}. Yellow and red arrowheads point to anterograde and retrograde peroxisome movement respectively. (**C,D**) Kymographs analyses of peroxisome transport in wildtype (**C**) and *actr10* mutants (**D**). (**E--G**) Peroxisome transport parameters were similar between *actr10* mutants and wildtype siblings, though a slight reduction in retrograde distance and anterograde velocity were noted (ANOVA; mean ± SEM shown). The proportion of peroxisomes moving in the retrograde direction was reduced as well, though not significantly (ANOVA; mean ± SEM shown; *p*=0.07). (**H,I**) Kymographs of Lamp1-labeled vesicle movement at 4dpf. (**J--L**) Lamp1 vesicles were transported similarly between wildtype and *actr10* mutants. An increase in the proportion of these vesicles in mutants that were stationary during imaging was noted (*p*\<0.01; ANOVA; mean ± SEM shown). Number of larvae assayed is indicated on graphs. Scale bars = 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.22234.012](10.7554/eLife.22234.012)Video 5.Peroxisome motility in a 4 dpf wildtype larvae, related to [Figure 7](#fig7){ref-type="fig"}.Yellow arrowhead points to a peroxisome moving in the anterograde direction. Red arrowhead indicates a peroxisome moving in the retrograde direction. Scale bar = 10 µm**DOI:** [http://dx.doi.org/10.7554/eLife.22234.013](10.7554/eLife.22234.013)10.7554/eLife.22234.013Video 6.Peroxisome motility in a 4 dpf *actr10* mutant larva, related to [Figure 7](#fig7){ref-type="fig"}.Yellow arrowheads indicate peroxisomes moving in the anterograde direction. Red arrowhead marks peroxisome moving in the retrograde direction. Scale bar = 10 µm**DOI:** [http://dx.doi.org/10.7554/eLife.22234.014](10.7554/eLife.22234.014)10.7554/eLife.22234.014

Since we observed small changes in retrograde peroxisome transport, we wanted to further investigate the relationship between loss of Actr10 and loss of dynein/dynactin. To do this, we analyzed the ability of DHC and p150 null mutants to phenocopy *actr10* mutants. First, we compared *actr10* mutants to a previously isolated zebrafish DHC mutant, *dync1h1^mw20^* (hereafter referred to as *dync1h1*; [@bib20]). Unlike *actr10* mutants (see [Figure 1](#fig1){ref-type="fig"}), *dync1h1* mutants displayed rapid degeneration of pLL axons by 4 dpf, with pLL nerves extending less than half-way to the tail at this time-point ([Figure 8A,B](#fig8){ref-type="fig"}). Mitochondria do accumulate in distal axons of *dync1h1* mutants, as expected with global disruption of retrograde transport ([Figure 8F,G](#fig8){ref-type="fig"}). The disparity between *actr10* and *dync1h1* mutant axonal phenotypes argues that loss of Actr10 does not impact all dynein function in axons.10.7554/eLife.22234.015Figure 8.*dync1h1* and *p150a/b* mutants fail to phenocopy *actr10* mutants.(**A**) Wildtype larva at 4 dpf with full pLL axon extension into the tail. End of pLL nerve indicated by arrowhead. (**B**) Loss of DHC in *dync1h1* mutants results in pLL axon degeneration, leading to a truncated pLL nerve at 4 dpf. Small eyes are also apparent (red dotted line), as has been reported previously. (**C**) *p150a* mutants have small eyes (red outline) but pLL nerves are identical to wildtype siblings. (**D**) *p150b* mutants at 4 dpf with normal pLL nerves and no change in eye diameter. (**E**) *p150a/b* double mutants have truncated, thin pLL nerves with swellings along the length of axons and in terminals and are indistinguishable from *dync1h1* mutants. *p150a/b* mutants also show small eyes similar to *dync1h1* and *p150a* mutants. (**F,G**) *dync1h1* mutants display axon terminal swellings and mitochondrial accumulation compared to wildtype controls at 4 dpf. Arrows point to mitochondria rich, axonal swellings. Mitochondria are labeled by expression of *mito-TagRFP* (red on top F-J, white below F\`-J\`). (**H,I**) *p150a* and *p150b* single mutants have axon terminal morphology and mitochondrial localization in axon terminals similar to wildtype siblings. (**J**) Loss of both p150 paralogues (*p150a/b*; **J**) results in swollen axon terminals with increased mitochondrial density similar to *dync1h1* mutants (**G**). (**K--N**) Kymograph analyses of mitochondrial transport in *p150* mutants. (**O**) The proportion of mitochondria moving in both the anterograde and retrograde direction in pLL axons is significantly decreased in *p150a/b* double mutants (ANOVA with Tukey HSD post-hoc contrasts). (**P**) The number of mitochondria in pLL axons is decreased in *p150a* mutants compared to wildtype siblings (ANOVA with Tukey HSD post-hoc contrasts; \**p*\<0.05). The number of mitochondria in pLL axons of *p150a/b* double mutants is dramatically reduced compared to wildtype siblings (ANOVA with Tukey HSD post-hoc contrasts; mean±SEM shown). (**Q,R**) Distance and velocity of limited residual mitochondrial movement is not significantly altered in *p150a/b* mutants compared to wildtype siblings (ANOVA with Tukey HSD post-hoc contrasts; mean ± SEM shown). Scale bars in A-E = 100 µm. Scale bars in F-J = 10 µm. Number of larvae assayed is indicated on graphs.**DOI:** [http://dx.doi.org/10.7554/eLife.22234.015](10.7554/eLife.22234.015)

We then compared the *actr10* mutant phenotype to loss of dynein-dynactin interaction using zebrafish *p150* mutants. There are two orthologs of *p150* in zebrafish, *p150a* and *p150b*. These paralogues are highly similar at the amino acid level but have slightly different expression patterns: while both are ubiquitously expressed, *p150b* is enriched in developing (1 and 2 dpf) and mature (4 dpf) neurons while *p150a* is enriched only in mature neurons 4 dpf ([Figure 9A--F](#fig9){ref-type="fig"}). To determine whether loss of p150 phenocopies the *actr10* mutant, we assayed single and double *p150* mutants using a *p150a* mutant described previously ([@bib8]; [@bib53]) and a novel *p150b* mutant we engineered (*p150b^nl16^*). Loss of *p150a* alone has no discernable effect on axons or mitochondrial localization ([Figure 8C,H](#fig8){ref-type="fig"}). We used CRISPR-Cas9 technology ([@bib18]) to create a deletion in exon 3 of *p150b*, which resulted in a frame-shift and premature stop site. *p150b* single mutants are indistinguishable from wild-type siblings at 4 dpf, with normal axon terminals and no abnormalities in mitochondrial localization ([Figure 8D,I](#fig8){ref-type="fig"}). This strain does not have the small eye phenotype observed in *dync1h1* and *p150a* mutants ([Figure 8A--D](#fig8){ref-type="fig"}; [@bib8]; [@bib20]; [@bib53]). Unlike single *p150* mutants, *p150a/b* mutants are phenotypically similar to *dync1h1* mutants, with truncated pLL axons and mitochondrial accumulation at axon ends ([Figure 8E,J](#fig8){ref-type="fig"}). This confirms the reliance of mitochondria on the dynein-dynactin complex for retrograde movement and demonstrates that *actr10* mutants do not phenocopy the axon truncation phenotype of dynein or dynactin loss of function mutants.10.7554/eLife.22234.016Figure 9.*p150a* and *p150b* expression in zebrafish embryos and larvae.(A,C,E,E\`) *p150a in situ* hybridization shows ubiquitous expression at 1 and 2 dpf, with a slight enrichment in neurons of the pLL ganglion at 4 dpf. (B,D,F,F\`) *p150b* is enriched in developing neurons with low level expression ubiquitously at all stages assayed. pLL and anterior lateral line ganglia are indicated by an arrowhead or arrow respectively in all. \*=ear. Higher magnification views of the ear, pLL ganglia, and anterior lateral line ganglia shown in insets in B\`, D\`, E\`, and F\`. Scale bars in A-F = 100 µm. Scale bars in B\` and D\`-F\`=20 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.22234.016](10.7554/eLife.22234.016)

We then analyzed the effect of p150 loss of function on mitochondrial transport in pLL axons. Mitochondria were tagged with TagRFP using zygotic injection of the *5kbneurod:mito-TagRFP* plasmid and kymograph analysis was performed on videos acquired through live imaging ([Figure 8K--N](#fig8){ref-type="fig"}). Unlike loss of Actr10, *p150a/b* double mutants had an almost complete cessation of mitochondrial movement in the anterograde and retrograde directions ([Figure 8N,O](#fig8){ref-type="fig"}). In addition, we noted a dramatic loss of mitochondria from the central portion of axons in *p150a/b* double mutants, likely because of the strong defect in anterograde mitochondrial transport ([Figure 8P](#fig8){ref-type="fig"}). Analyses of transport parameters revealed no change in the distance or velocity of the residual mitochondrial movement in either direction ([Figure 8Q,R](#fig8){ref-type="fig"}). The dramatic loss of all mitochondrial movement in *p150a/b* mutants, specifically reductions in both the anterograde and retrograde pools, is not observed in *actr10* mutants, which have only a reduction in the retrograde mitochondrial pool (see [Figure 4](#fig4){ref-type="fig"}). Furthermore, two cargos known to localize normally in *actr10* mutants, pJNK and Lamp1 (see [Figure 2](#fig2){ref-type="fig"}), accumulate in in *p150a/b* mutant axon terminals ([Figure 10A--D](#fig10){ref-type="fig"}), indicating that the retrograde transport of these cargos is perturbed by loss of dynein-dynactin interaction. Therefore, our phenotypic, *in vivo* transport, immunolabeling and biochemical data fail to support the argument that loss of Actr10 impacts all dynein-dynactin function in axons and, instead, supports a specific requirement for Actr10 in mitochondrial retrograde transport in this neuronal compartment.10.7554/eLife.22234.017Figure 10.pJNK and Lamp1 accumulate in *p150a/b* pLL axon terminals.(**A,B**) pJNK accumulates in axon terminals at 4 dpf in *p150a/b* double mutants. NM3 shown. (**C,D**) Lamp1 accumulates in NM4 axon terminals at 5 dpf in *p150a/b* double mutants. Arrows point to axon terminals in wildtype and *p150a/b* double mutants in all. Axons are labeled by the *neurod:egfp* BAC transgene (green). Lamp1 and pJNK are show in red in A-D and white in A\`-D\`. Scale bars = 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.22234.017](10.7554/eLife.22234.017)

Mitochondria fail to attach to the dynein-dynactin complex in actr10 mutants {#s2-4}
----------------------------------------------------------------------------

The specific effect of Actr10 depletion on retrograde mitochondrial transport frequency led us to ask if Actr10 is necessary to attach this organelle to the dynein motor complex. We addressed this question using mitochondrial fractionation from whole larvae ([Figure 11A](#fig11){ref-type="fig"}; [@bib37]). Analysis of fractions revealed equal levels of p150 in the input and heavy fractions between wildtype and *actr10* mutants. Strikingly, in *actr10* mutants, p150 was largely lost from the mitochondrial fraction with a concomitant increase of p150 to the light fraction, which contains all cellular components not pelleted under low centrifugation speeds ([Figure 11B,C](#fig11){ref-type="fig"}). This result demonstrates the necessity of Actr10 for mitochondrial attachment to dynactin.10.7554/eLife.22234.018Figure 11.Actr10 is essential for mitochondria-dynactin interaction.(**A**) Schematic of whole embryo mitochondrial fractionation. (**B**) While the level of p150 in the input and heavy fractions are comparable between wildtype and *actr10* mutants, p150 is shifted from the mitochondrial to light fraction in *actr10* mutants. ATPβ western blot from the same extracts (bottom) serves as a mitochondrial loading control. (**C**) Quantification of p150 intensity (normalized to mitochondrial loading) in *actr10* mutants relative to wildtype. (**D**) Quantification of p150 intensity (normalized to mitochondrial loading) in mRFP-Actr10△7 expressing embryos relative to those expressing mRFP-Actr10. (**E**) Schematic and sequence of the △7 region in Actr10. (**F**) Immunoprecipitation of EGFP-Actr10 deletion constructs from HEK293T cells identified the △7 region as critical for Actr10's interaction with the dynactin complex (n = 4 replicates). (**G**) In zebrafish embryos, mRFP-Actr10△7, expressed by zygotic injection of *in vitro* synthesized mRNA, was unable to interact with dynactin (top). mRFP-Actr10 and mRFP-Actr10△7 (middle) and p150 (bottom) are all present at similar levels. Bead only (no 1°) immunoprecipitation controls shown. (**H**) Actr10△7 is able to interact with mitochondria in zebrafish embryos as assayed by mitochondrial fractionation. ATPβ mitochondrial loading control (bottom).**DOI:** [http://dx.doi.org/10.7554/eLife.22234.018](10.7554/eLife.22234.018)

To better define the mechanism of dynactin-Actr10-mitochondrial interaction, we identified the domain in Actr10 necessary for association with the dynactin complex using immunoprecipitation of deletion constructs (overlapping deletion of 40 amino acid regions) from HEK293T cells. Whereas Actr10△7--△10 deletions showed reduced binding to dynactin, Actr10△7 most consistently failed to immunoprecipitate dynactin in all experiments ([Figure 11E,F](#fig11){ref-type="fig"}; n = 4). As this result was somewhat variable in HEK cells, we confirmed the necessity of this domain for Actr10-dynactin interaction *in vivo* using immunoprecipitation of Actr10 and Actr10△7 from embryo lysates. This revealed a loss of interaction between Actr10△7 and dynactin, demonstrating the reliance of Actr10 on this region for interaction with dynactin ([Figure 11G](#fig11){ref-type="fig"}; n = 3). Finally, if Actr10 is a part of the scaffold necessary for mitochondria-dynactin interaction, a separate mitochondrial binding domain likely exists in Actr10. If this is the case, Actr10 lacking the dynactin binding domain should maintain its interaction with mitochondria. To address this, we assayed the ability of Actr10△7 to bind mitochondria using mitochondrial fractionation. mRFP-Actr10 and mRFP-Actr10△7, expressed using zygotic microinjection of respective mRNAs, were both present in the mitochondrial fractionation ([Figure 11D,H](#fig11){ref-type="fig"}; n = 2), arguing that separate protein domains exist in Actr10 which are necessary for interaction with dynactin and mitochondria. This data supports a role for Actr10 in binding mitochondria to dynactin for retrograde mitochondrial transport.

Drp1 functions with Actr10 in mitochondrial retrograde transport {#s2-5}
----------------------------------------------------------------

It is unlikely that Actr10 binds directly to mitochondria as it does not have predicted transmembrane or other membrane-associated domains. Rather, similar to Kinesin-1-mitochondrial attachment, there are likely partner proteins that facilitate this interaction ([@bib15]; [@bib16]). Literature searches revealed a particularly strong association between Drp1 (Dynamin related protein 1), a GTPase associated with mitochondrial fission, and mitochondrial localization. Specifically, a lysine to alanine mutation at amino acid 38 in Drp1 (mimicking a constitutively GDP-bound form) causes clustering of mitochondria in the perinuclear region of fibroblasts in a microtubule-dependent manner ([@bib46]; [@bib49]). Using immunoprecipitation, we demonstrated that Drp1 interacts with Actr10, with strongly enhanced interaction between Actr10 and the Drp1^K38A^ variant ([Figure 12A](#fig12){ref-type="fig"}; n = 3 replicates in independent experiments; ([@bib46], [@bib45]).10.7554/eLife.22234.019Figure 12.Drp1 functions with Actr10 in mitochondrial retrograde transport.(**A**) EGFP-Actr10 interacts with myc-Drp1 in HEK293T cells. The K38A mutation in Drp1 strengthens this interaction (n = 3 replicates). (**B,C**) Expression of Drp1^K38A^-mRFP causes mitochondrial clustering in wildtype pLL neuron cell bodies at 4 dpf compared to an mRFP only control (**B**). (**D,E**) Though mitochondrial morphology is abnormal in *actr10* mutant pLL neuron cell bodies (**D**), expression of Drp1^K38A^-mRFP does not cause clustering of this organelle (**E**). (**F--I**) While expression of Drp1^K38A^-mRFP in wildtype larvae causes loss of mitochondria from the proximal axon compared to mRFP only controls (**F,G**), mitochondrial number is unaffected by Drp1^K38A^-mRFP expression in *actr10* mutants (**H,I**). Arrowheads point to mitochondria in mRFP-expressing axons. Mitochondria are labeled by expression of a mitochondrial targeting sequence tagged with EGFP (*5kbneurod:mito-EGFP*; green in B-I, white in B\`-I\`). (**J**) Quantification of mitochondrial number normalized to mitochondrial size in the proximal axon (ANOVA with post-hoc contrasts; mean ± SEM shown). Scale bars = 10 µm. Number of larvae assayed is indicated on graphs.**DOI:** [http://dx.doi.org/10.7554/eLife.22234.019](10.7554/eLife.22234.019)

Next, we asked whether Drp1 works with Actr10 to regulate mitochondrial retrograde transport *in vivo*. To address this, we examined the genetic interaction between Drp1 and Actr10 in mitochondrial localization in pLL neurons. We reasoned that if Drp1 and Actr10 function in the same pathway, Drp1 manipulation would impact the location of mitochondria in wildtype but not *actr10* mutant axons. We expressed Drp1-mRFP, Drp1^K38A^-mRFP, and cytoplasmic mRFP (control) in pLL neurons using injection of a plasmid encoding the respective open reading frame under an inducible promotor. Mitochondria were labeled by *5kbneurod:mito-EGFP* co-injection. In wild-type larvae, expression of Drp1^K38A^-mRFP caused mitochondrial clustering in the perinuclear region, phenotypically similar to the results observed in cultured fibroblasts ([Figure 12B,C](#fig12){ref-type="fig"}; [@bib46]; [@bib49]). In contrast, Drp1^K38A^-mRFP expression did not alter mitochondrial localization in *actr10* mutant pLL neurons ([Figure 12D,E](#fig12){ref-type="fig"}). If Drp1^K38A^ mediates retrograde mitochondrial movement, we predicted its expression would induce movement of mitochondria from the proximal axon into the cell body, leading to loss of mitochondrial occupation of the axon. Indeed, expression of Drp1^K38A^ caused a substantial decrease in the number of mitochondria per micron in wildtype but not *actr10* mutant axons ([Figure 12F--J](#fig12){ref-type="fig"}). Notably, *actr10* mutants already have reduced mitochondrial occupation of pLL axons which could impact the fraction of mitochondria capable of motility in this assay. More definitive analyses of Drp1's role in Actr10-dependent mitochondrial motility will be the subject of continued investigation. Together, the biochemical and genetic interaction between Actr10 and Drp1^K38A^ support a model in which Drp1, in its GDP-bound state, modulates dynein-based mitochondrial localization via an Actr10-dependent mechanism.

Discussion {#s3}
==========

Using genetics, immunolabeling, biochemistry, and *in vivo* imaging of cargo movement, we have identified Actr10 as a mediator of retrograde mitochondrial transport. In the absence of this dynactin pointed end protein, mitochondrial retrograde transport frequency is selectively disrupted, leading to accumulation of this organelle in axon terminals. Importantly, the anterograde transport of mitochondria, the localization and transport of other cargos assayed, the localization of dynein-dynactin components as well as dynein retrograde movement are all largely intact in the absence of Actr10, arguing for a role for Actr10 in mitochondrial retrograde transport in axons. Additionally, Actr10 maintains its ability to interact with mitochondria without being incorporated into the dynactin complex, suggesting a specific role for this protein in linking this organelle to the retrograde motor. Finally, we demonstrated that Actr10, perhaps through interaction with Drp1, links mitochondria to the dynactin complex. Our study brings us a step closer to understanding how unidirectional mitochondrial transport is mediated in axons to maintain a functional neural circuit.

Actr10s role in mitochondrial retrograde transport {#s3-1}
--------------------------------------------------

We provide multiple pieces of evidence supporting a function for Actr10 in mitochondrial transport. First, mitochondria are the only cargo analyzed whose localization or retrograde transport is significantly perturbed with loss of Actr10. If dynein-mediated cargo movement was generally disrupted, other cargos, including lysosomes and dynein itself, would fail to move in the retrograde direction as well. Second, the axonal phenotype of dynactin and dynein loss-of-function mutants is vastly different from *actr10* mutants: *dync1h1* and *p150a/b* mutants display pLL nerve degeneration at 4 dpf while *actr10* mutants do not. Third, loss of dynactin-dynein interaction in *p150a/b* mutants impedes all mitochondrial transport, a phenotype that is not observed in *actr10* mutants. Fourth, neither the localization of dynein and dynactin nor the retrograde movement of dynein are perturbed with loss of Actr10. Lastly, we identified a domain in Actr10 (△7) that is essential for interaction with the dynactin complex but inconsequential for interaction with mitochondria. This piece of data is critical as it demonstrates that Actr10 can interact with this organelle independently of dynactin, arguing for a direct role for this protein in mitochondria-dynactin interaction. Together, our data argue that Actr10 is necessary for dynactin-dependent, retrograde transport of mitochondria in axons.

Actr10 could directly link mitochondria to dynactin or potentially facilitate this interaction through other dynactin pointed end proteins, such as p62. p62 is of particular interest in this regard as it is predicted to rely on Actr10 for binding to the dynactin complex ([@bib48]). Based on our current data, we cannot rule out a role for this protein in mitochondrial transport. Furthermore, Actr10 interacting proteins, including p62, could have additional impacts on mitochondrial transport parameters, including transport distance. As noted above, *actr10* mutants have slight deficits in the distance moved by mitochondria in both the anterograde and retrograde directions. While we cannot definitively ascertain the underlying mechanism of this disruption, at least three possibilities exist. First, bidirectional transport distance could be affected by the abnormal localization of mitochondria. Mitochondrial localization directly affects local levels of ATP, which in turn could compromise the processive activity of ATP-dependent motors necessary for long distance transport. Another possibility is local deficits in mitochondrial activity: if mitochondrial health is compromised, this could account for the bidirectional transport deficits of mitochondria. Finally, it is possible that Actr10 or its interacting proteins, such as p62, regulate motor engagement. It is largely thought that cargos typically have anterograde and retrograde motors attached simultaneously and direction of transport is attributed to regulation of motor engagement. More frequent oscillations in motor engagement due to loss of Actr10 or Actr10 interactors could account for the shortened distances moved by mitochondria in both directions. At this point, we do not have a full explanation for these transport parameter alterations but they are a topic of continued interest.

Multiple roles for Actr10 in the cell {#s3-2}
-------------------------------------

Our data does not preclude a function for Actr10 in the retrograde transport of additional cargos in axons or other roles for Actr10, which could vary based on a number of factors including cell type and developmental stage. Of particular interest is a potential role for Actr10 in peroxisome transport through interaction with Drp1. While we did not find a statistically significant difference in the proportion of peroxisomes moving in the retrograde direction, there was a trend towards a decrease in this population. As Drp1 is known to localize to peroxisome membranes as well ([@bib41]), it will be interesting to further explore the interplay between these proteins and the transport of these highly related organelles. In addition to cargo transport, one predicted function for Actr10, based on structural and biochemical data, is in capping the Arp1 filament ([@bib48]). In support of this role, knockdown of Actr10 using siRNA in Cos7 cells resulted in dissociation of the dynactin complex pointed end ([@bib57]). Additionally, studies in the fungi *neurospora* and *aspergillus* demonstrated that loss of Actr10 phenocopies the abnormal nuclear positioning observed with loss of dynein ([@bib23]; [@bib58]). Similarly, zebrafish *actr10* mutants display the small eye phenotype observed in *dync1h1* and *p150a* mutants (see [Figure 8](#fig8){ref-type="fig"} and [@bib8]; [@bib20]). Finally, similar to loss of p150, knockdown of Actr10 resulted in multipolar spindle formation in Cos7 cells ([@bib57]). Together, these data could imply that Actr10 is in fact necessary for all dynein-dynactin activity through stabilizing the Arp1 filament; however, they could also be interpreted to mean that Actr10 is necessary for regulation of Arp1-membrane interaction. Indeed, Actr10 has been shown to regulate Arp1-membrane interaction ([@bib5]) and the zebrafish eye phenotype in the *p150a* mutant is due to a defect in interkinetic nuclear migration ([@bib8]). This type of function for Actr10 could also explain the nuclear positioning defect in the *actr10* loss of function studies in fungi ([@bib23]; [@bib58]). Therefore, rather than purely serving a stabilizing role for the dynactin complex, Actr10 may modulate both Arp1 interaction with the nuclear membrane and mitochondria-dynactin binding in axons. How these functions are disparately regulated in different cell types, in different cellular compartments and/or at varying developmental stages is still unclear.

Given the previous data implicating Actr10 in Arp1 capping and subsequent dynactin stability and dynein function ([@bib48]; [@bib57]; [@bib58]), we were presented with the challenge of confirming that Actr10 has a specific function in mitochondrial retrograde transport and reconciling our work with these previous studies. As outlined above, our evidence for a role for Actr10 in mitochondrial transport specifically includes: (1) *actr10* mutant axons are not phenotypically identical to *dync1h1* or *p150* mutants; (2) mitochondrial retrograde, but not anterograde, transport is disrupted in *actr10* mutants while all mitochondrial movement is inhibited in *p150a/b* mutants; and (3) localization and transport of all other cargos are not disrupted in *actr10* mutants. Together, these results argue that loss of Actr10 does not impact all dynein-dynactin function. In addition, a variant of Actr10 lacking the dynactin binding domain retains its ability to interact with mitochondria, further substantiating a direct role for this protein in mitochondria-dynactin interaction. Together, our data argue that Actr10 participates in mitochondrial attachment to the retrograde motor protein complex in neurons in addition to potentially facilitating Arp1 capping and nuclear positioning in other contexts.

Drp1 and Actr10 function together to regulate mitochondrial retrograde transport {#s3-3}
--------------------------------------------------------------------------------

The interaction between Drp1 and Actr10 in mitochondrial retrograde transport may provide a link between mitochondrial movement and mitochondrial fission. Originally, we investigated the role of Drp1 in retrograde mitochondrial transport as previous studies revealed the unique ability of this GTPase to elicit mitochondrial localization to microtubule minus ends ([@bib46], [@bib45]). Upon further investigation, it became apparent that a select number of proteins implicated in mitochondrial fission and fusion, including Drp1, have been shown to be essential for mitochondrial transport. Specifically, the fusion-related protein Mitofusin binds to the Miro-Milton complex and is necessary for mitochondrial movement ([@bib30]). Similar to Miro and Milton, loss of Mitofusin results in decreased anterograde and retrograde mitochondrial transport in cultured neurons ([@bib30]). Interestingly, the inner mitochondrial membrane protein Opa1, also necessary for mitochondrial fusion, does not participate in transport ([@bib30]). Thus, eliminating mitochondrial fusion itself does not impact mitochondrial movement; rather mitochondrial outer membrane proteins may have dual roles in fusion-fission dynamics and transport.

Similarly, our work in conjunction with other studies supports the argument that Drp1 participates in both mitochondrial fission and retrograde mitochondrial transport. Drp1 translocates to mitochondria where it can bind to receptors Fis1 and Mff ([@bib25]). In its GTP-bound form, it then oligomerizes, forming a constrictable collar necessary for fission during which GTP is exchanged for GDP ([@bib19]). We found that a Drp1 variant incapable of binding GTP stimulates mitochondrial accumulation at the nuclear periphery, linking fission with transport. Our genetic interaction data suggest that Actr10 functions with Drp1 in this process, though further experiments are necessary to confirm this. Rather than Actr10 working with Drp1 to regulate mitochondrial localization, it is also possible that loss of Actr10 results a decrease in the motile pool of mitochondria in axons upon which Drp1^K38A^ could work. We cannot differentiate between these possibilities at this point. Nevertheless, given the intriguing data generated here, it is tempting to speculate that, upon the GTP-GDP transition, not only do mitochondria undergo fission but Drp1 also recruits the retrograde motor protein complex through interaction with Actr10 to facilitate separation of these daughter mitochondria. The precise nature of Drp1-Actr10 interaction and the role of this interaction in mitochondrial retrograde transport is a subject of current investigation.

Conclusions {#s3-4}
-----------

The coordinated regulation of mitochondrial transport is necessary for the formation and maintenance of active neural circuits. Our work identifies Actr10 as a crucial protein for mitochondrial interaction with the dynein-dynactin complex, regulating retrograde transport. In addition, we argue that the role of Actr10 is specific and not due to a general loss of dynactin stability or dynein function. The strongest pieces of evidence supporting this assertion are the ability of Actr10 to bind mitochondria in the absence of dynactin and the disparate nature of the *actr10-dync1h1* and *actr10-p150a/b* mutant phenotypes in axons. In addition, we identified Drp1, a GTPase implicated in mitochondrial fission, as an Actr10 interactor with a potential role in mitochondrial retrograde transport. Together with previous studies on mitochondrial motility, a complex picture is emerging in which mitochondrial transport and fission/fusion are dependent on a core group of proteins, with an independent set of proteins regulating mitochondrial docking. In conclusion, further work is crucial to understanding how mitochondrial transport and dynamics are orchestrated in axons, which will ultimately allow us to better understand how this critical organelle is positioned and maintained. As mitochondrial transport and dynamics have been implicated in neurological disorders, a more complete mechanistic understanding of their regulation will provide insight into disease pathology.

Materials and methods {#s4}
=====================

Zebrafish husbandry and strains {#s4-1}
-------------------------------

Adult \*AB and WIK strains were maintained at 28.5°C and spawned according to standard protocols ([@bib55]). ENU mutagenesis and mutant screening were performed as described previously ([@bib33]). Additional strains used include: *TgBAC(neurod:egfp)^nl1^* ([@bib35]), *actr10^nl15^*, *dync1h1^mw20^* ([@bib20]), *p150a* (also known as *mok^s309^*; ([@bib8]; [@bib53]), and *p150b^nl16^*.

RNA-seq based identification of the actr10^nl15^ mutation and genotyping {#s4-2}
------------------------------------------------------------------------

RNAseq-based mapping was performed according to established protocols ([@bib29]). *actr10* heterozygotes (\*AB background) were crossed to WIKs to generate a mapping strain. Heterozygous F1 hybrids were identified using pair wise crosses. Eighty wildtypes/heterozygotes and 80 *actr10* mutants were obtained from a single mapping pair. These larvae were lysed at 4 dpf in Trizol according to the manufacturer's protocol. mRNA was extracted in phenol:chloroform:isoamyl alcohol and twice in chloroform before the pellet was redissolved in 20 µL of RNase/DNase free water. Sequencing was performed by the OHSU Massively parallel sequencing core on an Illumina HiSeq2000, generating approximately 30 million reads per condition. From this RNAseq data, RNAmapper identified a single nucleotide change in the start codon of the *actr10* gene in the *actr10^nl15^* mutant pool. The mutation (validated by sequencing and restriction digest of individual samples) completely segregated with the mutant phenotype. For experiments, *actr10* mutants were identified by genotyping according to the following protocol: PCR amplification of the region around exon 1 of the *actr10* locus resulted in a 374 bp product (forward primer: 5'-CTGTTTTCGGATGAACTGCCTG; reverse primer: 5'-AGATGCTCTTCGTCTTCTGGCTA. The *actr10* mutation inserts a HaeIII cut site. Digestion with HaeIII generates wildtype (209 bp) and *actr10* mutant (195 bp) bands.

Cloning the zebrafish ortholog of *actr10*, plasmid production, TALEN synthesis, and mRNA synthesis {#s4-3}
---------------------------------------------------------------------------------------------------

The full-length open reading frame of *actr10* was cloned from a 2 dpf zebrafish cDNA library and ligated into the pSC-A-amp/kan vector (Agilent Technologies; forward primer: 5'-AAATGCCCTTGTTTGAA; reverse primer: 5'-TTTCTCAGTGGAGAAGG). All expression and mRNA synthesis vectors were constructed using Gateway compatible cloning as described ([@bib22]). For Actr10 expression, the Actr10 open reading frame was PCR amplified with BP arms and inserted into the Gateway compatible 3'-entry vector pDONRP2R-P3 (forward primer: 5'-ggggacaagtttgtacaaaaaagcaggctAAATGCCCTTGTTTGAA; reverse primer: 5'-ggggaccactttgtacaagaaagctgggtaTTTCTCAGTGGAGAAGG). Other constructs used included: *5kbneurod:mito-TagRFP* (modified from ([@bib12]); *5kbneurod:mRFP-dync1li1V2* ([@bib9]); *Hsp701:mRFP-polyA; Hsp701:Drp1-mRFP; Hsp701:Drp1^K38A^-mRFP*; and *CMV/SP6:EGFP-dync1i2b*. They were constructed as described here. The zebrafish *dync1i2b* ortholog was cloned into the pDONRP2P3 3' entry vector using BP-competent primers (forward primer: 5'-ggggacagctttcttgtacaaagtggAGATGGCTCCCGTTTTAGAGAAG; reverse primer: 5'-ggggacaactttgtataataaagttgtTCATGCCTCGTTCTCTGTC) and a 2 dpf zebrafish cDNA library. The zebrafish Drp1 ortholog was cloned from 2 dpf cDNA, sequence verified, and cloned into the pDONR221 middle entry vector using BP cloning (forward primer: 5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCAACGCGATGGAGGCTCTTA; reverse primer: 5'-GGGGACCACTTTGTACAAGAAAGCTGGGTACCACAAGTGCGTC). To generate *Drp1^K38A^*, the middle entry vector was mutated to change Lysine 38 to Alanine (forward primer: 5'-CGCAGAGTAGCGGGGCGAGTTCAG; reverse primer: 5'-CCAAAACTGAACTCGCCCCGCTAC). All expression plasmids were constructed by LR cloning using the *5kbneurod* ([@bib31]), *CMV/SP6*, or *Hsp701* 5' entry vectors and the pDestTol2pA2 destination vector. mRNA was synthesized using the SP6 mMessage Machine kit (Life Technologies). TALENs targeting exon 1 of *actr10* were designed using freeware (<http://www.talendesign.org>) and synthesized as described ([@bib7]); Tal1 target: AATTTCTGCTGATAAAATGC; Tal2 target: GGGCAGCGGAGGAGA).

Generation of the *p150^nl16^* mutant and genotyping {#s4-4}
----------------------------------------------------

The *p150b^nl16^* mutant was generated using CRISPR/Cas9-mediated genome editing as described ([@bib18]; [@bib44]). Guide RNA targeting exon 3 (GGCGAGGGCAGCGCTCCCAC) of the *p150b* locus was produced using a PCR-mediated scaffold method as described ([@bib13]). Cas9 mRNA ([@bib3]) was produced using the SP6 mMessage machine kit. Zygotes derived from *p150a* (*moks^309^*) heterozygous outcrosses were injected with 10 pg guide RNA and 100 pg Cas9 mRNA at the one cell stage. Progeny were raised until adulthood and outcrossed to wildtypes to generate larvae. Larvae were genotyped using PCR amplification of the exon 3 locus (forward primer: 5'-CGTGAGTGAGCTCTTGGTCTG; reverse primer: 5'-GCGTCTATAACCATGTTTGACCTTG) and cut with MwoI to identify insertions/deletions. Changes to the guide RNA target result in loss of the MwoI cut site in *p150b* mutants: wildtype (164 bp + 64 bp) from *p150b* mutants (224 bp).

*In situ* hybridization and antibody labeling {#s4-5}
---------------------------------------------

*In situ* hybridization and antibody labeling were done according to established protocols ([@bib9]). The *actr10* open reading frame was used for in situ hybridization. An \~800 base pair portion the 3'UTR of *p150a* and *p150b* were used for *in situ* hybridization of these paralogues. Antibodies used were: α-Dynein heavy chain (Protein Tech; \#12345--1-AP); α-p150 (BD Transduction Laboratories; \#610473); α-Lamp1 (Iowa Hybridoma Bank, \#1D4B); α-pJNK (Cell Signaling Technology, \#9251S); α-GFP (Aves Labs Inc., \#GFP-1020); α-DsRed (Clontech, \#632496); α-Cytochrome c (BD Biosciences, \#556432); α-GFP (Fisher Scientific, \#A-11122); α-c-myc (Santa Cruz, \#sc-40); and α-ATPβ (Abcam; \#ab128743).

Cell culture, immunoprecipitation and mitochondrial fractionation {#s4-6}
-----------------------------------------------------------------

HEK293T cells (Sigma Aldrich; \#12022001; identity authenticated by STR-PCR) were cultured according to standard protocols in DMEM with 50 U/mL Pen-Strep. Cells tested mycoplasma free (MycoAlert Mycoplasma Detection Kit; Lonza; L07-218). This human cell line was used for its transfection ease and results were confirmed in vivo. Transfection was done in a 6-well plate using 2.5 µg total DNA and 5 µL of Lipofectamine2000 per well according to manufacturer's protocols (Thermo Fisher; \#11668027). The mammalian GFP-Actr10 clone was used previously ([@bib57]) and obtained from Addgene (plasmid \#51398). *Drp1-myc* and *Drp1^K38A^-myc* expression constructs were previously described ([@bib46]). GFP-Actr10 deletion constructs were made using the QuikChange II XL Site-Directed Mutagenesis kit (Agilent, \#200521).

Mitochondrial fractionation was performed according to established protocols ([@bib37]). Briefly, for each biological replicate 100 wildtype/heterozygous or *actr10^nl15^* mutant larvae were disrupted in 700 µL MB buffer (210 mM mannitol, 70 mM sucrose, 1 mM EDTA, 10 mM HEPES pH = 7.5 and protease inhibitors) using a 26 gauge needle. After removal of the input fraction, lysates were subjected to increasing centrifugation speeds to fractionate mitochondria from a heavy and light fractions. The mitochondrial fraction was washed once in fresh MB buffer prior to addition of Laemmli buffer to the pellet and heat denaturation. Extracts were run on a 10% acrylamide gel, transferred to PVDF membrane, and incubated with antibodies prior to developing with the West Pico Substrate (Thermo Fisher; \#34080). After initial development, membranes were washed in water and PBS/0.1% Tween prior to incubation with the α-ATPβ antibody.

*In vivo* analysis of axonal transport {#s4-7}
--------------------------------------

Axonal transport analyses were done as described ([@bib9]). Briefly, zygotes were injected with plasmids to express cargos of interest tagged with fluorescent proteins. At 4 dpf, larvae (each a biological replicate) were screened for pLL ganglion expression of cargo fusions and imaged using a 63X/NA1.2 water objective on an FV1000 confocal microscope (Olympus). All imaging was done in a single z-plane, allowing acquisition at 2--4 frames per second, as required by the Nyquist sampling theorem ([@bib34]). Kymograph analyses of cargo movement were performed using Metamorph (Molecular Devices).

Transmission electron microscopy {#s4-8}
--------------------------------

Zebrafish larvae at 5 dpf were fixed and prepared for TEM analysis using standard protocols ([@bib6]). Samples were embedded and sectioned from the tail of the larvae. An ultramicrotome was used to cut 1000 nm sections, which were then stained with Toluidine Blue to ensure the presence of neuromasts. Subsequently, 70 nm sections were cut and placed on copper mesh grids. Grids were stained with uranyl acetate for one hour and then each grid was cleaned with milliQ water for 45 s. The next day, grids were stained with Sato's lead stain for 15 min and again cleaned with milliQ water. The Washington University Center for Cellular Imaging Jeol JEM-1400 (Jeol USA) electron microscope was used to observe samples and an AMT V601 camera captured images.

Image and statistical analyses {#s4-9}
------------------------------

Volumetric analyses to determine mean fluorescence intensity of immunolabeling was done using Imaris (Bitplane). For this analysis, a surface rendering was done using expression of the *neurod:egfp* transgene in axon terminals and the mean fluorescence intensity was determined. Background from the same channel was subtracted prior to analysis. For quantification of western blots, mean intensity of was determined for signal and background using ImageJ. Statistical analyses were done in JMP. Prior to parametric analyses, data normality and variance were determined. Parametric data was analyzed using ANOVAs with Tukey-Kramer HSD contrasts for multiple comparisons. Non-parametric data was analyzed using Wilcoxon/Kruskal Wallis Tests. Image analyses and figure preparation was done using ImageJ, Adobe Photoshop, and Adobe Illustrator.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Regulation of mitochondria-dynactin interaction and mitochondrial retrograde transport in axons\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by Tanya Whitfield as Reviewing Editor and Jonathan Cooper as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

This interesting study describes a forward screen in zebrafish that identifies a component of the retrograde transport machinery. The authors propose that the Actr10 protein acts as a linker between mitochondria and the dynein/dynactin complex. Specifically, the authors set out to show that in Actr10 mutant zebrafish, retrograde transport of mitochondria, but not other cargo, is specifically compromised. Dynein transport is apparently normal in *actr10* mutants, and mutants in dynein and dynactin components have more severe and widespread phenotypes than *actr10*, supporting the notion that Actr10 functions specifically in transport of mitochondria. The authors suggest that Acrt10 interacts physically with the dynactin complex and brings it to mitochondria. Furthermore, the authors identify a region of the Actr10 protein that is required for physically interacting with the dynactin complex, but not mitochondria. Finally, biochemical and genetic experiments demonstrate that Actr10 interacts with the mitochondrial protein Drp1 and that a putative gain-of-function Drp1 mutant requires Actr10 to increase retrograde transport, supporting the idea that Drp1 recruits Actr10 to mitochondria.

Essential revisions:

1\) The results showing that the trafficking effects are specific to mitochondria are not completely convincing, and require further experiments and controls. It is not clear that mitochondria accumulate more than other cargoes in axon swellings. The images should be analysed more quantitatively, avoiding potential effects of swelling size by normalising to area/volume. Anterograde and retrograde traffic should be quantified. (After discussion, it was felt that kymograph analysis would be very suitable here; if there were no comparable deficit in retrograde transport of other cargoes, the conclusion about specificity would be supported further. EM analysis might be useful but is not essential.)

2\) Critical controls are absent from several figures. Please see the specific comments from Reviewer 2.

Please see the individual reviews, which are appended below, for further information.

Reviewer \#1:

The conclusion about mitochondrial specificity would be even stronger if the authors analyzed more cargo using kymograph analysis-not just lysosomes and JNK. In a previous paper, the authors looked at a wide variety of cargo (Drerup and Nechiporuk, 2013, PLoS Genetics), so this should be technically feasible.

In addition to the kymograph analysis, the authors could quantify enrichment in an alternative, less biased way. For example, perhaps they could outline the entire neuromast and determine the average pixel intensity for each marker over the entire structure in *actr10* and wt. Another good way to do it would be to normalize the intensity of each marker by taking a ratio to a volume-filling reporter, such as cytoplasmic GFP. If they are correct, the cyt10 to GFP ratio should be higher in *actr10* mutants relative to wt, but the other markers should be the same in both genotypes.

One issue that the authors may wish to address a bit more, either through discussion or experiments, is the generalizability of these results. Is mitochondrial transport also affected in other neurons in the Actr10 mutant fish? What is the ultimate consequence of these defects to the neuron? Do they eventually degenerate? What is the ultimate fate of these fish? Is the Actr10 locus associated with any human diseases?

Reviewer \#2:

I have raised a few queries into methodological and interpretative issues below. One particular issue is the \"mitochondria specific\" effect that is not supported by the Lamp1 and pJNK staining. I suggest the authors reconsider this.

Results section and [Figure 2](#fig2){ref-type="fig"}. I think it is problematic to say that accumulations don\'t contain other cargoes. 2I and 2K both show labeling that colocalises with the axonal swelling. Indeed comparing the pJNK and Lamp1 staining in *actr10* embryos ([Figure 2](#fig2){ref-type="fig"}) with the same staining in p150a/b ([Figure 8](#fig8){ref-type="fig"}) seems to show exactly the same effect (although the opposite conclusion is drawn).

The analysis shown in the graphs in [Figure 2](#fig2){ref-type="fig"} seems to have selected regions outside of swellings for LAMP and pJNK, but inside a swelling for Mitochondria. Is this a strange choice?

In my opinion the swelling doesn\'t just contain mitochondria. This is true for other genetic mutations that give rise to axonal swelling in the literature.

In relation to the specificity of *actr10* mutation for mitochondria in comparison to pJNK and LAMP it would be necessary to demonstrate that transport of these cargoes is not affected in *actr10* mutant axons. This could be achieved using kymograph analysis.

EM could also be used to identify the contents of these swellings. Alternatively, the authors should remove the claim that these swellings are purely a consequence of mitochondrial accumulation.

Results section and [Figure 3D](#fig3){ref-type="fig"}. Ideally [Figure 3D](#fig3){ref-type="fig"} should show at least one retrograde mitochondrion to allow us to see the rate of retrograde transport. This is potentially important in relation to the point about reversals below.

Results section and [Figure 4F](#fig4){ref-type="fig"}. To be more certain of the result, the rescue of axonal swelling in a cell specific fashion in neuromasts should be quantified. A single example is given. It would be appropriate to determine the efficiency of rescue in at least 10 neuromasts from 10 embryos.

Results section and [Figure 5D](#fig5){ref-type="fig"}. This panel shows the swollen axon phenotype, and these swollen axons contain high levels of p150. I would say that this suggests that p150 is mislocalised.

[Figure 5J](#fig5){ref-type="fig"}. Studying the transport parameters and looking at the kymograph suggests that the effect of *actr10* mutation is to increase the number of reversals of direction in puncta undergoing retrograde movement. Looking at retrograde puncta in I and J, they both show pauses, but in I these are brief and only include small reversals in direction. However in J the retrograde puncta seem to frequently reverse direction. To investigate this it would be appropriate to measure the number of reversals per mito/minute for both anterograde and retrograde cargoes. If correct, this observation would suggest that *actr10* is needed for the \"tug of war\" between kinesin and dynein motors, and loss of *actr10* leads to more kinesin mediated movement of cargoes that would normally be transported by dynein. This is consistent with the idea that the dynactin complex regulates co-ordinated movement of cargoes in vivo (e.g. Gross JCB 2002).

[Figure 5N](#fig5){ref-type="fig"} and O. Immunoprecipitations using \"beads only\" i.e. omitting the primary antibody are an essential control. GFP is notoriously \"sticky\" in these types of experiment.

[Figure 5O](#fig5){ref-type="fig"}. In the co-IP of p150 with exogenous i2b it is critical to include the relevant control. i.e. western blot showing that the p150 signal is only present when i2b is pulled down. (co-IP of uninjected *actr10* extracts performed at the same time as co-IP from i2b injected embryos.) This is in addition to the comment above.

[Figure 9](#fig9){ref-type="fig"}. This is an important figure, using biochemistry to address localization of p150 in mutants.

A&B: I am confused by the fact that the heavy fraction is strongly enriched for mitochondria. This suggests incomplete lysis of embryos. Probably just a technical issue, because 9F does not show the same enrichment?

There appears to be less p150 in *actr10* lysate. This in itself might affect transport and needs to be investigated.

The loss of p150 from the mito fraction is striking, but the appearance in the supernatant cannot be correctly interpreted without using non-mitochondrial loading controls. I would suggest probing these blots with the following antibodies to ensure these fractions are \"pure\". (i) a nuclear protein that should label the heavy fraction (ii) another mito protein to confirm ATPβ. (iii) tubulin (DM1A) to confirm supernatant and mito fractions.

These controls will also confirm equal loading for WT and *actr10*, particularly important in the case of the light fraction.

C-D: control IPs are not presented to show how much p150 is immunoprecipitated using \"beads only\". This needs to be shown for each experiment. Also the level of GFP immunoprecipitated in Δ7 to Δ13 is much lower, so it is difficult to compare the efficiency of p150 IP.

E: Again controls are missing. Is this specific?

[Figure 10A](#fig10){ref-type="fig"}. To interpret the K38A result correctly there needs to be a panel showing WCE for GFP-*actr10*. Beads only controls (no primary antibody) are also important here.

[Figure 10J](#fig10){ref-type="fig"}. I find interpretation of this difficult. It shows that K38A impairs mito transport in WT cells, but since there are already less mitos in the *actr10* axons it is less compelling to say that there is no effect of K38A because of a loss of interaction. i.e. if the effect of mutant *actr10* on mitos is independent of the effect of DRP1 won\'t we still get the same result?

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Regulation of mitochondria-dynactin interaction and mitochondrial retrograde transport in axons\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Jonathan Cooper (Senior editor), Tanya Whitfield (Reviewing editor), and two reviewers.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below (see comments from Reviewer 2). In particular, it is essential that the immunoprecipitation experiments shown in [Figures 6N and O](#fig6){ref-type="fig"} are shown with all the controls. Please add the necessary controls and label the blots as has been done for [Figure 11G](#fig11){ref-type="fig"}, i.e. indicate which antibodies have been used for the immunoprecipitation and which for the immunoblot.

Reviewer \#1:

The authors have been responsive to reviewers and improved the manuscript in several notable ways: First, they have performed electron microscopy to demonstrate that mitochondria accumulate in terminals of *actr10* mutants; second, they have re-analyzed image data with quantification methods that are more convincing and added new measures of transport that support their conclusions; third, they have added critical controls for biochemical experiments; finally, they have revised the text to emphasize alternative interpretations of key conclusions. This is now a thorough and convincing manuscript that identifies a key protein regulating the transport of specific axonal cargoes to maintain healthy axons, making this work of interest to both cell biologists and neuroscientists.

Reviewer \#2:

The authors have modified the manuscript, and it shows considerable improvement.

I find 2 areas that require further explanation

1\) Reversals:

Results section paragraph four, -- Unclear- 0/100 micron in mutants?

Needs to be only in moving mitochondria not per 100 micron, since there are less moving in mutants there is less chance for reversal?

2\) IP:

My request: \"it is critical to include the relevant control. i.e. western blot showing that the p150 signal is only present when i2b is pulled down. (co-IP of uninjected *actr10* extracts performed at the same time as co-IP from i2b injected embryos.)\"

As far as I can tell the new data presented in [Figure 6](#fig6){ref-type="fig"} currently shows no p150 blot data for the additional controls?

10.7554/eLife.22234.021

Author response

Essential revisions:

1\) The results showing that the trafficking effects are specific to mitochondria are not completely convincing, and require further experiments and controls. It is not clear that mitochondria accumulate more than other cargoes in axon swellings. The images should be analysed more quantitatively, avoiding potential effects of swelling size by normalising to area/volume. Anterograde and retrograde traffic should be quantified. (After discussion, it was felt that kymograph analysis would be very suitable here; if there were no comparable deficit in retrograde transport of other cargoes, the conclusion about specificity would be supported further. EM analysis might be useful but is not essential.)

To address this issue, we reanalyzed our immunolabeling experiments to control for axonal volume, assayed the transport of additional cargos in axons, and perform TEM analyses of mutant axon terminals. Altogether, these data demonstrated that there is no identifiable change in the amount of other cargos in *actr10* mutant axon terminals. While we cannot rule out a role for Actr10 in the movement of another cargo, these data indicate that not all cargo rely on Actr10 for retrograde transport.

2\) Critical controls are absent from several figures. Please see the specific comments from Reviewer 2.

To address this comment, we repeated a subset of these experiments with bead only controls as recommended. These additional controls confirmed our previous observations and are now included in the revised manuscript. Please find below an outline of our specific responses and where the corrections have been made in the text and figures. [Figures 3](#fig3){ref-type="fig"} and [7](#fig7){ref-type="fig"} are new while [Figures 2](#fig2){ref-type="fig"}, [6](#fig6){ref-type="fig"} (previously 5), and 11 (previously 9) have had significant changes. Major changes in the text of the manuscript are in blue font.

Please see the individual reviews, which are appended below, for further information.

Reviewer \#1:

The conclusion about mitochondrial specificity would be even stronger if the authors analyzed more cargo using kymograph analysis-not just lysosomes and JNK. In a previous paper, the authors looked at a wide variety of cargo (Drerup and Nechiporuk, 2013, PLoS Genetics), so this should be technically feasible.

We performed live imaging experiments to analyze the transport of two additional cargos in response to this review, peroxisomes and late endosomes/lysosomes labeled by Lamp1. JNK transport, as performed in our earlier work, was not feasible at 4 dpf, the time-point at which our other experiments were performed in this paper (our previous JNK analysis was done at 2 dpf). The results of our experiments were very informative. First, we analyzed peroxisome transport. Surprisingly, there were small alterations in the distance of peroxisome retrograde transport and velocity of anterograde peroxisome movement ([Figure 7](#fig7){ref-type="fig"}). Upon further literature investigation, it became apparent that peroxisomes and mitochondria actually share many similarities, including membrane proteins. One particular membrane localized protein, Drp1, which is shared by these different organelles, is implicated in Actr10-dependent mitochondrial transport in our work. This hints at a possibility of peroxisome transport being dependent on Actr10-Drp1 interaction (noted in the Discussion section), which will be the focus of our future work. Because peroxisome transport experiments were somewhat difficult to interpret, we analyzed the transport of a third cargo, lysosomes/late endosomes. This analysis demonstrated no change in Lamp-1 labeled lysosome/late endosome transport. Together, these experiments determined that, while peroxisome transport showed a trend towards decreases in retrograde transport frequency (p=0.07; [Figure 7](#fig7){ref-type="fig"}), not all cargo transport relies on this Actr10. These additional experiments are described in subsection "Dynein localization and motility does not rely on Actr10" and shown in [Figure 7](#fig7){ref-type="fig"}.

In addition to the kymograph analysis, the authors could quantify enrichment in an alternative, less biased way. For example, perhaps they could outline the entire neuromast and determine the average pixel intensity for each marker over the entire structure in actr10 and wt. Another good way to do it would be to normalize the intensity of each marker by taking a ratio to a volume-filling reporter, such as cytoplasmic GFP. If they are correct, the cyt10 to GFP ratio should be higher in actr10 mutants relative to wt, but the other markers should be the same in both genotypes.

We agree this type of analysis is indeed more suitable for signal quantification in axon terminals and thank the reviewer for this suggestion. As suggested by the Reviewer, we used volumetric analyses in Imaris software to determine the mean fluorescent intensity relative to the volume of axon terminals (determined using the cytoplasmic EGFP fill to create a "surface") for Cytochrome c (mitochondria), Lamp1, and pJNK in [Figure 2 E-G](#fig2){ref-type="fig"}. This analysis revealed elevated Cytochrome c levels but no change in pJNK or Lamp1 in *actr10* mutants. In addition, we used the same approach to analyze the amounts of Dynein heavy chain and p150 in [Figure 6 E and F](#fig6){ref-type="fig"} to demonstrate no change in the localization of these components of the dynein motor complex in *actr10* mutants.

One issue that the authors may wish to address a bit more, either through discussion or experiments, is the generalizability of these results. Is mitochondrial transport also affected in other neurons in the Actr10 mutant fish? What is the ultimate consequence of these defects to the neuron? Do they eventually degenerate? What is the ultimate fate of these fish? Is the Actr10 locus associated with any human diseases?

As Reviewer suggested, we elaborated briefly on the general mutant phenotype in the Results section. Specifically, we stated that the mutant is not homozygous viable and both CNS and PNS axons have these large swellings. Due to the limitations of imaging in other types of neurons (those positioned deeper within the embryo) with the current protocols we have in place, we did not visualize mitochondrial transport in other neuronal subtypes at this time. While we do not discuss it in the manuscript, the axons in the *actr10* mutants do not degenerate prior to larval death. In addition, the *actr10* locus is not associated with any disease states save a short report demonstrating transcription of *actr10* is increased in an in vitro model of prion disease (Brown et al., Hum Mol Genet., 2014).

Reviewer \#2:

I have raised a few queries into methodological and interpretative issues below. One particular issue is the \"mitochondria specific\" effect that is not supported by the Lamp1 and pJNK staining. I suggest the authors reconsider this.

Results section and [Figure 2](#fig2){ref-type="fig"}. I think it is problematic to say that accumulations don\'t contain other cargoes. 2I and 2K both show labeling that colocalises with the axonal swelling. Indeed comparing the pJNK and Lamp1 staining in actr10 embryos ([Figure 2](#fig2){ref-type="fig"}) with the same staining in p150a/b ([Figure 8](#fig8){ref-type="fig"}) seems to show exactly the same effect (although the opposite conclusion is drawn).

The analysis shown in the graphs in [Figure 2](#fig2){ref-type="fig"} seems to have selected regions outside of swellings for LAMP and pJNK, but inside a swelling for Mitochondria. Is this a strange choice?

In my opinion the swelling doesn\'t just contain mitochondria. This is true for other genetic mutations that give rise to axonal swelling in the literature.

In relation to the specificity of actr10 mutation for mitochondria in comparison to pJNK and LAMP it would be necessary to demonstrate that transport of these cargoes is not affected in actr10 mutant axons. This could be achieved using kymograph analysis.

*EM could also be used to identify the contents of these swellings. Alternatively, the authors should remove the claim that these swellings are purely a consequence of mitochondrial accumulation.*

The points raised by this reviewer are critical to clarify and address for the submitted manuscript. Importantly, we do not to claim that mitochondria are the only cargo which is abnormally localized or transported in *actr10* mutants. Based on our analyses, we can only say that the other cargos we analyzed are localized and transported normally and dynein is capable of moving normally in the retrograde direction. In addition, no other cargo appears significantly accumulated in *actr10* mutant axon terminals based on our TEM analyses. However, it is possible that movement of other cargo, not analyzed in our studies, is also interrupted in *actr10* mutants. We would like to clarify that our main motivation for the analysis of other cargos was to show that loss of Actr10 does not impact all dynein-mediated cargo transport. This point is now discussed throughout the manuscript.

In addition, to more clearly show that at least some non-mitochondrial cargos are localized normally in *actr10* mutants, we reanalyzed the data using volumetric surface analyses in Imaris as described above. This type of analysis of fluorescence intensity within axon terminals defined by the presence of cytoplasmic EGFP (on the same images analyzed previously) demonstrated that Cytochrome c immunofluorescence is significantly increased in *actr10* mutants while Lamp1 and pJNK are not. This is now shown in [Figure 2](#fig2){ref-type="fig"}.

We also analyzed the transport of two additional cargos, peroxisomes and lysosomes, using our established protocols. The results are discussed above in regard to Reviewer 1 point 1 and depicted in [Figure 7](#fig7){ref-type="fig"}.

Finally, we collaborated with Amy Herbert and Kelly Monk (now co-authors on the paper) to perform TEM analyses of the PNS axon terminals in *actr10* mutants. These analyses clearly show a preponderance of mitochondria in the axon terminal swellings of lateral line axons. This is shown in [Figure 3](#fig3){ref-type="fig"} of our revised manuscript and discussed in subsection "Mitochondria accumulate in actr10 mutant axon terminals due to failed retrograde transport". While other cargos may in fact accumulate or move abnormally as well, to date we have no evidence of what that cargo may be. This is now stated in subsection "Actr10s role in mitochondrial retrograde transport":

"Our data does not preclude a function for Actr10 in the retrograde transport of as of yet unidentified cargo in axons or other roles for Actr10 in cells, which could vary based on a number of factors including cell type and developmental stage.".

Results section and [Figure 3D](#fig3){ref-type="fig"}. Ideally [Figure 3D](#fig3){ref-type="fig"} should show at least one retrograde mitochondrion to allow us to see the rate of retrograde transport. This is potentially important in relation to the point about reversals below.

We have used a different kymograph to show mitochondrial transport in *actr10* mutants in what is now [Figure 4D](#fig4){ref-type="fig"}.

Results section and [Figure 4F](#fig4){ref-type="fig"}. To be more certain of the result, the rescue of axonal swelling in a cell specific fashion in neuromasts should be quantified. A single example is given. It would be appropriate to determine the efficiency of rescue in at least 10 neuromasts from 10 embryos.

We have now specified the number of axon terminals analyzed in wildtype and mutant animals as well as the number of biological replicates in subsection "Actr10 functions autonomously in neurons to regulate axon morphology and mitochondrial localization "of the revised manuscript.

Results section and [Figure 5D](#fig5){ref-type="fig"}. This panel shows the swollen axon phenotype, and these swollen axons contain high levels of p150. I would say that this suggests that p150 is mislocalised.

We quantified the p150 fluorescence intensity using volumetric analyses in Imaris software. This quantification is shown in [Figure 6](#fig6){ref-type="fig"} of the revised manuscript and demonstrates there is no difference in the level of p150 in *actr10* mutant axon terminals relative to controls.

*[Figure 5J](#fig5){ref-type="fig"}. Studying the transport parameters and looking at the kymograph suggests that the effect of actr10 mutation is to increase the number of reversals of direction in puncta undergoing retrograde movement. Looking at retrograde puncta in I and J, they both show pauses, but in I these are brief and only include small reversals in direction. However in J the retrograde puncta seem to frequently reverse direction. To investigate this it would be appropriate to measure the number of reversals per mito/minute for both anterograde and retrograde cargoes. If correct, this observation would suggest that actr10 is needed for the \"tug of war\" between kinesin and dynein motors, and loss of actr10 leads to more kinesin mediated movement of cargoes that would normally be transported by dynein. This is consistent with the idea that the dynactin complex regulates co-ordinated movement of cargoes* in vivo *(e.g. Gross JCB 2002).*

We appreciate the question and think the analysis of reversals adds to the value of the manuscript. To address this issue, we quantified the number of reversals in mitochondrial and dynein movement in the revised manuscript. The results are now reported in the text. We observe no change in reversal frequency of mitochondria or dynein-positive cargos in *actr10* mutants in our imaging experiments. Rather, based on the population analyses shown in [Figure 4](#fig4){ref-type="fig"}, it appears that mitochondria which fail to attach to the retrograde motor either move in the anterograde direction or become stationary. This could align well with the tug of war model in so much as failure of mitochondria to attach to cytoplasmic dynein leads to a loss of the ability of this motor to participate in the tug of war and increased anterograde mitochondrial transport.

[Figure 5N and O](#fig5){ref-type="fig"}. Immunoprecipitations using \"beads only\" i.e. omitting the primary antibody are an essential control. GFP is notoriously \"sticky\" in these types of experiment.

[Figure 5O](#fig5){ref-type="fig"}. In the co-IP of p150 with exogenous i2b it is critical to include the relevant control. i.e. western blot showing that the p150 signal is only present when i2b is pulled down. (co-IP of uninjected actr10 extracts performed at the same time as co-IP from i2b injected embryos.) This is in addition to the comment above.

The need for bead only controls was duly noted. To address this concern, we repeated the specified immunoprecipitation experiments with no primary (bead only) controls. These experiments confirmed that i2b-GFP can interact with the dynein complex and mRFP-Actr10 but not mRFP-Δ7Actr10 can interact with dynactin. These new Western blots are now shown in [Figures 6](#fig6){ref-type="fig"} and [11](#fig11){ref-type="fig"}.

[Figure 9](#fig9){ref-type="fig"}. This is an important figure, using biochemistry to address localization of p150 in mutants.

A&B: I am confused by the fact that the heavy fraction is strongly enriched for mitochondria. This suggests incomplete lysis of embryos. Probably just a technical issue, because 9F does not show the same enrichment?

The loss of p150 from the mito fraction is striking, but the appearance in the supernatant cannot be correctly interpreted without using non-mitochondrial loading controls. I would suggest probing these blots with the following antibodies to ensure these fractions are \"pure\". (i) a nuclear protein that should label the heavy fraction (ii) another mito protein to confirm ATPβ. (iii) tubulin (DM1A) to confirm supernatant and mito fractions.

These controls will also confirm equal loading for WT and actr10, particularly important in the case of the light fraction.

While the Reviewer raised a valid point, we believe that the observed variations in this experiment are due to the less stringent nature of this particular fractionation (compared to other, more precise methods such as sucrose gradient fractionation). This means that the mitochondrial fraction is only highly enriched for mitochondria relative to the other fractions as described by Prudent et al., 2013. The comparison to the mitochondrial loading control is therefore quite important as it shows that, relative to the amount of mitochondrial protein in this fraction specifically, the amount of p150 precipitated is dramatically reduced. To clarify this point, we have quantified the levels of p150 for each fraction relative to the input as well as mitochondrial loading in each fraction. This quantification is now shown as [Figure 11 C and D](#fig11){ref-type="fig"}. As the reviewer pointed out, mitochondria are also in the heavy fraction but this is likely due to the viscous nature of this fraction and, as the levels of p150 are also equal. In addition, we pointed out that the "light" fraction contains multiple cellular components.

There appears to be less p150 in actr10 lysate. This in itself might affect transport and needs to be investigated.

The amount of p150 in the *actr10* mutant fraction relative to wildtype siblings has now been quantified. In addition, the levels were normalized to the mitochondrial control (ATPβ) in the corresponding fractions to correct for any variation in loading. We felt it was important to normalize levels of p150 to mitochondria in each fraction, as the question we were addressing in this experiment was mitochondrial attachment to dynactin in the presence or absence of Actr10. This is now shown in [Figure 11 C](#fig11){ref-type="fig"}.

Additionally, the reviewer noted potential reduction in the p150 level in *actr10* mutants, as detected by Western blot ([Figure 6O](#fig6){ref-type="fig"}). As mentioned above, we have not seen any change p150 levels in axon terminals using whole embryo immunohistochemistry ([Figure 6F](#fig6){ref-type="fig"}). However, our western blots do show decreases in p150 in the whole embryos extracts relative to wildtype siblings. This is likely due to unequal protein loading: Rather than normalizing to total protein amounts, we chose to use the same number of embryos or larvae for wildtype and *actr10* mutants for each experiment. As the *actr10* mutants are slightly smaller than their wildtype counterparts, this could account for the differences. Our evidence to support this is the consistently lower levels of other proteins (i2b-GFP in [Figure 6O](#fig6){ref-type="fig"}) in *actr10* mutant extracts. This is now noted in the text in subsection "Dynein localization and motility does not rely on Actr10".

C-D: control IPs are not presented to show how much p150 is immunoprecipitated using \"beads only\". This needs to be shown for each experiment. Also the level of GFP immunoprecipitated in Δ7 to Δ13 is much lower, so it is difficult to compare the efficiency of p150 IP.

E: Again controls are missing. Is this specific?

Bead only (no primary antibody) controls are now shown for [Figure 11G](#fig11){ref-type="fig"} for IP of endogenous p150 by Actr10 and the Actr10 deletion construct. In addition, we noted in the revised text the variability of the immunoprecipitations from HEK cell extracts and further clarified the necessity of immunoprecipitating endogenous proteins to confirm the importance of the identified region for interaction with dynactin. This is now described in subsection "*Mitochondria fail to attach to the dynein-dynactin complex in actr10 mutants*".

[Figure 10A](#fig10){ref-type="fig"}. To interpret the K38A result correctly there needs to be a panel showing WCE for GFP-actr10. Beads only controls (no primary antibody) are also important here.

Because of time limitations, we were not able to repeat the Actr10-Drp1 coimmunoprecipitation with whole cell extracts probed for GFP; however this immunoprecipitation was replicated \>3 times with consistent results. This is now stated in the text in subsection "*Drp1 functions with Actr10 in mitochondrial retrograde transport*".

[Figure 10J](#fig10){ref-type="fig"}. I find interpretation of this difficult. It shows that K38A impairs mito transport in WT cells, but since there are already less mitos in the actr10 axons it is less compelling to say that there is no effect of K38A because of a loss of interaction. i.e. if the effect of mutant actr10 on mitos is independent of the effect of DRP1 won\'t we still get the same result?

With regard to Drp1K38A's impact on mitochondrial localization: we agree with the reviewer that the results of this experiment on their own are not entirely conclusive and should be interpreted with caution. This is now explicitly noted in the Discussion section of the revised manuscript. However, we also argue that there are multiple pieces of evidence to support our argument that Drp1 and Actr10 function together. 1) We show that the K38A mutation in Drp1 strengthens the interaction with Actr10. 2) In addition, work from others (Smirnova et al., 1998; Varadi et al., 2004) demonstrates that expression of Drp1^K38A^ relocalizes mitochondria in a microtubule-dependent fashion to microtubule minus ends, implicating the retrograde motor in this process. 3) Our data also shows that loss of Actr10 causes accumulation of mitochondria in axon terminals due to failed transport while Drp1^K38A^ causes accumulation of mitochondria in the cell body, likely due to increased retrograde movement. In contrast, if Drp1K38A functioned in a pathway parallel to Actr10, we would predict: 1) a further reduction in mitochondrial number in the axon; 2) a rescue (at least partial) in mitochondrial density in the axon terminals; and 3) mitochondrial accumulation in the cell body of *actr10* mutants, none of which are observed. Together, we use these data to argue that Drp1 in its GDP-bound form, is working with Actr10 to regulate mitochondrial localization in axons. This argument is now better articulated in the Discussion section.

We also outlined an addition caveat related to this experiment. It is possible that the motile pool of mitochondria (\~50% based on our work) is trapped in *actr10* mutant axon terminals, leading to the reduction in number in the axon capable of being transported. Without a motile pool, Drp1^K38A^ would not be able to decrease the number of mitochondria in the mutant axons to the same degree as in wildtype axons. This is now pointed out in the revised text. Future experiments using live imaging of mitochondrial transport would likely be able to discern between these possibilities.

Unfortunately, these types of experiments are not possible without the generation of additional stable transgenic lines which would take approximately 6 months.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

*The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below (see comments from Reviewer 2). In particular, it is essential that the immunoprecipitation experiments shown in [Figures 6N and O](#fig6){ref-type="fig"} are shown with all the controls. Please add the necessary controls and label the blots as has been done for [Figure 11G](#fig11){ref-type="fig"}, i.e. indicate which antibodies have been used for the immunoprecipitation and which for the immunoblot.*

In the revised manuscript, we have addressed the three additional concerns raised by reviewer two in response to our resubmission. First, we changed the way we analyzed mitochondrial reversal frequency to make it relative to the number of mitochondria present in the axons. Second, we performed the necessary control experiments for [Figure 6](#fig6){ref-type="fig"} panel O. In addition to wildtype and mutant immunoprecipitation results, we now show uninjected wildtype and bead only wildtype controls as requested. These panels are discussed in the figure legend for [Figure 6](#fig6){ref-type="fig"} and are shown in blue font. Finally, we changed our labeling scheme for the immunoprecipitation experiments in [Figure 6](#fig6){ref-type="fig"} to match those in [Figure 11](#fig11){ref-type="fig"} as requested.
